Universidade Estadual de Londrina is starting a new clinical trial of use of Budesonide diluted to maximum as clinical treatment of patients with chronic rhinosinusitis with polyoposis.
According to the European Position Paper on Rhinosinusitis and Nasal Polyps 2012, chronic rhinosinusitis in adults can be defined as an inflammation of the nasal mucosa and paranasal sinuses lasting 12 weeks or more, associated or not with nasal polyposis.
The present study aims to compare, through validated tests, the impact of the inclusion of nasal lavage with budesonide diluted in high volume in relation to placebo, in the improvement of the symptoms, signs, and quality of life of patients with chronic rhinosinusitis with polyposis. If effective, this therapy may decrease surgical indications and, consequently, health expenditures for the government.
It is expected that diluted budesonide improvement in the symptoms, signs, and quality of life of patients with chronic rhinosinusitis with polyposis.
The clinical trial will continue throughout August 10, 2025 and will be conducted by Marco Aurélio Fornazieri, Principal Investigator, Universidade Estadual de Londrina. The following patients may be included into the study: a minimum nasal polyp score (NPS) of 5 of a maximum of 8 for both nostrils (with at least a score of 2 for each nostril), and presence of at least two of the following symptoms prior to screening: nasal blockage / obstruction / congestion or rhinorrhea (anterior or posterior); facial / pressure pain; reduction or loss of smell. For exclusion criteria and more details: https://ichgcp.net/clinical-trials-registry/NCT05541419.